Exhibit 99.1

Contacts: Investors: Dean Schorno Genomic Health 650-569-2281 investors@genomichealth.com
Media:
Emily Faucette
Genomic Health
650-569-2824
media@genomichealth.com

Genomic Health Announces Third Quarter 2010 Financial Results and Business
Progress

Delivered Second Profitable Quarter with Net Income of $3.7 million

Product Revenue Increased 18%

Tests Delivered Grew 17% Driven by Increased Worldwide Sales of
Oncotype DX® Breast and Colon Cancer Tests

Conference Call Today at 4:30 p.m. ET

REDWOOD CITY, Calif., November 8, 2010 — Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2010.

Total revenue increased to $46.3 million in the third quarter of 2010, compared with $39.5 million in the third quarter of 2009. Product revenue was $45.8 million in the third quarter of 2010, an increase of 18 percent, compared with $38.9 million in the third quarter of 2009.

Net income was $3.7 million in the third quarter of 2010, compared with a net loss of $502,000 in the third quarter of 2009. Basic and diluted net income per share was $0.13 and $0.12, respectively, in the third quarter of 2010, compared with basic and diluted net loss per share of $0.02 in the third quarter of 2009.

“Our strong third quarter results reflect an increase in revenues and test volume across all segments of our business and increasing reimbursement worldwide,” said Kim Popovits, President and Chief Executive Officer of Genomic Health. “We delivered profit for the second consecutive quarter while continuing to invest in our global commercial infrastructure as well as multiple research and development initiatives aimed at expanding our reach to cancer patients in new markets throughout the world.”

Additional Third Quarter 2010 Financial Results

Total operating expenses for the third quarter of 2010 were $42.9 million, including cost of product revenues of $8.9 million, compared with total operating expenses for the comparable period in 2009 of $40.1 million, including cost of product revenues of $8.3 million. Included in operating expenses for the third quarter of 2010

were non-cash charges of $4.5 million, including $2.7 million of stock-based compensation expense and $1.8 million of depreciation and amortization expenses, compared with non-cash charges for the same period in 2009 of $4.2 million, including $2.5 million of stock-based compensation expense and $1.7 million of depreciation and amortization expenses.

Cash and cash equivalents and short-term investments at September 30, 2010 increased by $12.3 million to $69.7 million, compared with $57.4 million at December 31, 2009.

Financial Results for Nine Months Ended September 30, 2010

Total revenue for the nine months ended September 30, 2010 was $131.0 million, compared with $110.0 million for the first nine months of 2009. Product revenue for the nine months ended September 30, 2010 was $128.6 million, compared with $107.5 million for the first nine months of 2009, an increase of 20 percent.

Net income was $2.6 million for the nine months ended September 30, 2010, compared with a net loss of $9.1 million for the first nine months of 2009. Basic and diluted net income per share was $0.09 for the nine months ended September 30, 2010, compared with basic and diluted net loss per share of $0.32 for the first nine months of 2009.

Commercial Progress

• Delivered more than 14,730 Oncotype DX^® test results in the third quarter of 2010, an increase of 17 percent, compared with more than 12,600 test results delivered in the third quarter of 2009.

• Established contracts with the Blue Cross Blue Shield plans of Delaware, Florida, and Montana, and with Blue Cross of Northeastern Pennsylvania (NEPA), for estrogen-receptor positive node-negative breast cancer, including patients with micrometastases.

• Established a contract with EmblemHealth for certain estrogen-receptor positive breast cancer patients providing in-network benefit coverage for approximately 3.3 million lives in the Northeast.

     Oncotype DX Breast Cancer Updates

• The NCI-sponsored Eastern Cooperative Oncology Group completed enrollment of more than 10,000 early-stage breast cancer patients from more than 900 sites on four continents in the TAILORx clinical trial.

• Signed contracts for payment with several hospitals in the United Kingdom, Ireland and Mexico; and an additional payor in Greece.

• Presented positive results from first European clinical decision impact study of the Oncotype DX breast cancer test in Spain at the European Society for Medical Oncology (ESMO) Congress, demonstrating a more than 30 percent change in chemotherapy treatment recommendations, consistent with previously reported results in the U.S. and Israel.

• Presented positive results from an exploratory cost effectiveness analysis of the Oncotype DX breast cancer test in Australia and from a cost-benefit assessment in Singapore at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific Conference in September.

• Presented results at the Interamerican Breast Cancer Conference in July confirming that the distribution of Recurrence Score^® results in Latin American breast cancer patients is consistent with those observed in the U.S.

• Initiated a clinical decision impact study with researchers in Australia.

     Oncotype DX Colon Cancer Update

• Secured reimbursement from a leading public insurer in Greece covering more than 20 percent of the population for stage II colon cancer.

Product Pipeline, Peer-Reviewed Publications and Medical Meeting Highlights

• Received acceptance from the Society of Urologic Oncology to present initial results from prostate cancer gene identification study at its upcoming annual meeting on December 9.

• Initiated sample processing for large clinical trial in ductal carcinoma in situ (DCIS) breast cancer and plan to report results in the first half of 2011.

• Completed sample processing for a second recurrence study in stage II colon cancer and plan to report results in 2011.

• The National Comprehensive Cancer Network (NCCN) issued their first breast cancer treatment guidelines intended for patient use “recommending Oncotype DX because it has been tested and determined to be able to predict which women can safely undergo chemotherapy.”

• The Journal of Clinical Oncology published results of a study demonstrating that quantitative reporting for HER2 gene expression, as measured by the company’s Oncotype DX breast cancer test, has a high degree of concordance with fluorescence in situ hybridization (FISH).

• Presented results at the ASCO Breast Cancer Symposium in October of a study describing the wide variation of Recurrence Score results in rare breast cancer subtypes.

• Presented collective findings at the ESMO Congress in October from five studies of more than 3,000 patients that were used to develop and validate the Oncotype DX 12-gene colon cancer Recurrence Score as an independent predictor of recurrence in stage II colon cancer that provides value beyond other available measures.

• Presented results at the Beyond the Genome conference in October of two studies demonstrating the feasibility of identifying candidate expression biomarkers using next generation sequencing technology with standard tumor specimens that are routinely collected in clinical practice.

• Seven abstracts were accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS) December 8-10.

Conference Call Details

To access the live conference call on November 8 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1(224) 357-2389 internationally. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately two hours after the call through November 15, and may be accessed by dialing (800) 642-1687 from the United States and Canada or +1(706) 645-9291 internationally. The replay passcode is 19819777.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s Web site at http://investor.genomichealth.com/eventdetail.cfm?eventid=87666. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a life science company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. As of September 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 175,000 Oncotype DX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to increasing reimbursement worldwide; the company’s ability to continue to invest in its global commercial infrastructure and multiple research and development initiatives aimed at expanding its reach to cancer patients in new markets throughout the world; the outcome, success or

results of clinical trials and the timing of such activities; the applicability of clinical study results to actual outcomes; and the ability of the company’s tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the impact of the economy on our business; our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; our success retaining current contracts or levels of reimbursement coverage for our tests; the risks and uncertainties associated with the regulation of our tests by FDA; the impact of healthcare legislation on our business; our ability to compete against third parties; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

# # #

Genomic Health, Inc.

Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2010			2009			2010			2009
	(Unaudited)						(Unaudited)
REVENUES:
Product revenues	$	45,773		$	38,910		$	128,553		$	107,529
Contract revenues		544			607			2,432			2,436
Total revenues		46,317			39,517			130,985			109,965
OPERATING EXPENSES:
Cost of product revenues		8,853			8,301			25,927			24,019
Research and development		8,180			9,120			23,953			27,007
Selling and marketing		17,336			15,313			52,868			45,719
General and administrative		8,561			7,316			25,640			22,318
Total operating expenses		42,930			40,050			128,388			119,063
Income (loss) from operations		3,387			(533	)		2,597			(9,098	)
Interest and other income		70			116			219			591
Interest and other expense		(2	)		(22	)		(31	)		(109	)
Income (loss) before income taxes		3,455			(439	)		2,785			(8,616	)
Income tax provision (benefit)		(215	)		63			182			454
Net income (loss)	$	3,670		$	(502	)	$	2,603		$	(9,070	)
Basic net income (loss) per share	$	0.13		$	(0.02	)	$	0.09		$	(0.32	)
Diluted net income (loss) per share	$	0.12		$	(0.02	)	$	0.09		$	(0.32	)
Shares used to compute basic net income (loss) per share		28,832,280			28,579,045			28,783,676			28,538,915
Shares used to compute diluted net income (loss) per share		29,583,359			28,579,045			29,625,008			28,538,915

Genomic Health, Inc.
Condensed Consolidated Balance Sheets
(in thousands)

	As of		As of
	September 30, 2010		December 31, 2009
	(Unaudited)		(Unaudited)
Cash and cash equivalents	$	23,616	$	9,082
Short-term investments		46,095		48,366
Accounts receivable, net		12,311		11,123
Prepaid expenses and other current assets		5,539		5,677
Total current assets		87,561		74,248
Property and equipment, net		10,524		12,865
Restricted cash		500		500
Other assets		1,568		494
Total assets	$	100,153	$	88,107
Accounts payable	$	2,539	$	1,304
Accrued expenses and other current liabilities		14,503		14,940
Deferred revenues		1,685		2,238
Notes payable		43		225
Other liabilities		1,437		891
Stockholders’ equity		79,946		68,509
Total liabilities and stockholders’ equity	$	100,153	$	88,107

The condensed consolidated balance sheet at December 31, 2009 has been derived from the audited consolidated financial statements at that date included in the Company’s Form 10-K for the fiscal year ended December 31, 2009.